Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 10/20 | 0.69 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.62 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5573990 | 1.00 | VDR (0.69) | VDRHDAC6HDAC3HDAC2 | |
| SCHEMBL5573969 | 0.91 | VDR (0.72) | VDRHDAC6HDAC3HDAC2 | |
| SCHEMBL5576214 | 0.91 | VDR (0.72) | VDRHDAC6HDAC3HDAC2 | |
| SCHEMBL5576236 | 0.87 | VDR (0.70) | VDRHDAC6HDAC3HDAC2 | |
| SCHEMBL7577083 | 0.86 | VDR (0.58) | VDR | |
| SCHEMBL5685088 | 0.86 | VDR (0.58) | VDR | |
| SCHEMBL13644207 | 0.85 | VDR (0.79) | VDRHDAC6HDAC3HDAC2 | |
| SCHEMBL13644209 | 0.85 | VDR (0.79) | VDRHDAC6HDAC3HDAC2 | |
| SCHEMBL13644205 | 0.85 | VDR (0.79) | VDRHDAC6HDAC3HDAC2 | |
| SCHEMBL13859925 | 0.84 | VDR (0.80) | VDRHDAC6HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030149006-A1 | New vitamin D derivatives with cyclic substructures in the side chains, process and intermediate products for their production, and the use for the production of pharmaceutical agents | STEINMEYER ANDREAS (US) | 2003-08-07 | — | — | US | claimed |
| US-20070093448-A1 | Complexes that consist of vitamin D compounds or analogs thereof with a 5Z,7E,10(19)-triene system and methylated derivatives of beta-cyclodextrin | SCHERING AG (DE) | 2007-04-26 | — | — | US | disclosed |
| US-7115758-B2 | Vitamin D derivatives with cyclic substructures in the side chains, process and intermediate products for their production, and the use for the production of pharmaceutical agents | SCHERING AG (DE) | 2006-10-03 | — | — | US | disclosed |
| EP-1362848-A1 | Process for the preparation of vitamin D derivatives | Schering Aktiengesellschaft (DE) | 2003-11-19 | — | — | EP | disclosed |
| US-20030149006-A1 | New vitamin D derivatives with cyclic substructures in the side chains, process and intermediate products for their production, and the use for the production of pharmaceutical agents | STEINMEYER ANDREAS (US) | 2003-08-07 | — | — | US | disclosed |
| US-6603031-B1 | Active metabolites of vitamin D2 and vitamin D3 and their synthetic derivatives have a proliferation- inhibiting and differentiation-stimulating action on tumor cells and normal cells, | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149006-A1 | New vitamin D derivatives with cyclic substructures in the side chains, process and intermediate products for their production, and the use for the production of pharmaceutical agents | CYP24A1, CYP2R1, VDR | VDR 3/4885HDAC6 3613/4885HDAC3 2650/4885 |
| US-20070093448-A1 | Complexes that consist of vitamin D compounds or analogs thereof with a 5Z,7E,10(19)-triene system and methylated derivatives of beta-cyclodextrin | VDR, CYP24A1, CYP2R1 | VDR 1/4885HDAC6 2080/4885HDAC3 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.